EPHA1 and neoplasm: With the list now containing a total of 19 relevant preclinical studies, EPHA2 is, undoubtedly, the most studied EPH/ephrin target in BC treatment, the targeting of which mainly results in cell death induction, tumor growth inhibition, as well as anticancer immune system response.